Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
HIV-1 infection induces a progressive disruption of the B cell compartment impairing long-term immune responses to routine immunizations. Depletion of specific memory B cell pools occurs during the 1st stages of the infection and cannot be reestablished by antiretroviral treatment. We reasoned that an early control of viral replication through treatment could preserve the normal development of the memory B cell compartment and responses to routine childhood vaccines. Accordingly, we evaluated the effects of different highly-active antiretroviral therapy (HAART) schedules in 70 HIV-1 vertically-infected pediatric subjects by B cell phenotypic analyses, antigen-specific B cell enzyme-linked immunosorbent spot (ELISpot) and ELISA for common vaccination and HIV-1 antigens. Initiation of HAART within the 1st year of life permits the normal development and maintenance of the memory B cell compartment. On the contrary, memory B cells from patients treated later in time are remarkably reduced and their function is compromised regardless of viral control. A cause for concern is that both late-treated HIV-1 controllers and noncontrollers loose protective antibody titers against common vaccination antigens. Timing of HAART initiation is the major factor predicting the longevity of B cell responses in vaccinated HIV-1-infected children.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Antiretroviral Therapy and Mortality among HIV-Infected Infants
Violari, A., Cotton, M. F., Gibb, D. M., Babiker, A. G., Steyn, J., Madhi, S. A., Jean-Philippe, P., & McIntyre, J. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800971 · Cited by 1,418
Duration of Humoral Immunity to Common Viral and Vaccine Antigens
Amanna, I. J., Carlson, N. E., & Slifka, M. K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066092 · Cited by 1,286 · cited 1×
“To assess whether this preserved memory B cell compartment is fully functional and able to differentiate into specific antibody secreting cells upon polyclonal stimulation in vitro, we performed B cell ELISpot assays against measles, an antigen directly correlated to the memory B cell percentage (29) and against HIV-1…”
MethodMoir, S., Ho, J., Malaspina, A., Wang, W., DiPoto, A. C., O'Shea, M. A., Roby, G., Kottilil, S., Arthos, J., Proschan, M. A., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072683 · Cited by 901
Measles Antibody: Reevaluation of Protective Titers
Chen, R. T., Markowitz, L. E., Albrecht, P., Stewart, J. A., Mofenson, L. M., Preblud, S. R., & Orenstein, W. A. (1990) · Journal of Infectious Diseases · doi:10.1093/infdis/162.5.1036 · Cited by 608
Neonatal and early life vaccinology
Siegrist, C.-A. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00028-7 · Cited by 593
Setting the stage: host invasion by HIV
Hladik, F., & McElrath, M. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2302 · Cited by 564 · cited 1×
“D HIV-1 infection, immunological functions are gradually lost with the depletion of CD4 T cells (1).”
BackgroundPeripheral development of B cells in mouse and man
Carsetti, R., Rosado, M. M., & Wardmann, H. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.0109.x · Cited by 473 · cited 2×
“The same analysis was performed for IgM memory B cells (CD19 , CD27 , IgM , IgD ) (23) and for switched memory B cells (CD19 , CD27 , IgM , IgD ).”
Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection
Titanji, K. (2006) · Blood · doi:10.1182/blood-2005-11-013383 · Cited by 293 · cited 2×
“During the natural course of HIV-1 infection, B cells undergo phenotypic alterations and loss of functionality, including depletion of memory B cell pools, which are responsible for the maintenance of serologic memory (3, 26, 27).”
BackgroundCapolunghi, F., Cascioli, S., Giorda, E., Rosado, M. M., Plebani, A., Auriti, C., Seganti, G., Zuntini, R., Ferrari, S., Cagliuso, M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.2.800 · Cited by 246 · cited 1×
“In this context, of particular interest is the observation that transitional B cells stimulated by CpG terminally differentiate into plasma cells producing natural antibodies with innate pneumoccoccal specificity (42).”
BackgroundLoss of memory (CD27) B lymphocytes in HIV-1 infection
De Milito, A., Mörch, C., Sönnerborg, A., & Chiodi, F. (2001) · AIDS · doi:10.1097/00002030-200105250-00003 · Cited by 215 · cited 1×
“During the natural course of HIV-1 infection, B cells undergo phenotypic alterations and loss of functionality, including depletion of memory B cell pools, which are responsible for the maintenance of serologic memory (3, 26, 27).”
BackgroundSelf-citationLuzuriaga, K., McManus, M., Catalina, M., Mayack, S., Sharkey, M., Stevenson, M., & Sullivan, J. L. (2000) · Journal of Virology · doi:10.1128/jvi.74.15.6984-6991.2000 · Cited by 209 · cited 1×
“This is a common phenomenon among HIV-1-infected infants receiving HAART early in life (21, 30).”
BackgroundThe human spleen is a major reservoir for long-lived vaccinia virus–specific memory B cells
Mamani-Matsuda, M., Cosma, A., Weller, S., Faili, A., Staib, C., Garçon, L., Hermine, O., Beyne-Rauzy, O., Fieschi, C., Pers, J.-O., et al. (2008) · Blood · doi:10.1182/blood-2007-11-123844 · Cited by 183
Immunization of children at risk of infection with human immunodeficiency virus.
Moss, W. J., Clements, C. J., & Halsey, N. A. (2003) · Europe PMC (PubMed Central) · Cited by 177
B Lymphocyte Dysfunctions in HIV Infection
De Milito, A. (2004) · Current HIV Research · doi:10.2174/1570162043485068 · Cited by 169
Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease
Moir, S., & Fauci, A. S. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.04.034 · Cited by 163 · cited 2×
“During the natural course of HIV-1 infection, B cells undergo phenotypic alterations and loss of functionality, including depletion of memory B cell pools, which are responsible for the maintenance of serologic memory (3, 26, 27).”
BackgroundPENTA guidelines for the use of antiretroviral therapy, 2004
Sharland, M., Blanche, S., Gattinara, G. C., Ramos, J. M., & Gibb, D. M. (2004) · HIV Medicine · doi:10.1111/j.1468-1293.2004.00227.x · Cited by 155 · cited 1×
“’’ All children were treated according to pediatric HIV-1 guidelines (44).”
BackgroundPrimary HIV-1 infection sets the stage for important B lymphocyte dysfunctions
Titanji, K., Chiodi, F., Bellocco, R., Schepis, D., Osorio, L. M., Tassandin, C., Tambussi, G., Grützmeier, S., Lopalco, L., & Milito, A. D. (2005) · AIDS · doi:10.1097/01.aids.0000191231.54170.89 · Cited by 154
Self-citationRodriguez‐Barradas, M. C., Musher, D. M., Lahart, C., Lacke, C. E., Groover, J. E., WATSON, D. A., BAUGHN, R. E., Cate, T. R., & Crofoot, G. E. (1992) · The Journal of Infectious Diseases · doi:10.1093/infdis/165.3.553 · Cited by 151 · cited 1×
“Finally, post vaccination pneumococcal IgG levels seem to be reduced in treatment naı̈ve and HAART-treated HIV-1-infected patients (40, 41).”
BackgroundMoir, S. L., Malaspina, A., Ho, J., Wang, W., DiPoto, A. C., O’Shea, M. A., Roby, G. A., Mican, J. M., Kottilil, S., Chun, T., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/526789 · Cited by 150 · cited 1×
“Highly-active antiretroviral therapy (HAART) reduces hypergammaglobulinemia (5) and increases the absolute B cell count (4, 6).”
BackgroundA Trial of Three Antiretroviral Regimens in HIV-1–Infected Children
Luzuriaga, K., McManus, M. M., MOFENSON, L. M., Britto, P., Graham, B., & Sullivan, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032706 · Cited by 145 · cited 1×
“Finally, post vaccination pneumococcal IgG levels seem to be reduced in treatment naı̈ve and HAART-treated HIV-1-infected patients (40, 41).”
BackgroundInternational perspectives, progress, and future challenges of paediatric HIV infection
Prendergast, A. J., Tudor‐Williams, G., Jeena, P. M., Burchett, S. K., & Goulder, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61051-4 · Cited by 144 · cited 1×
“Perinatal HIV-1 infection is acquired in the milieu of a developing immune system and consequently, in the absence of antiretroviral treatment, PHI in children results in higher levels of HIV-1 viremia compared with adults (28).”
BackgroundThe piglet as a model for B cell and immune system development
Butler, J. E., Lager, K. M., Splichal, I., Francis, D., Kacskovics, I., Sinkora, M., Wertz, N., Sun, J., Zhao, Y., Brown, W. R., et al. (2009) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2008.10.321 · Cited by 137
Leyendeckers, H., Odendahl, M., Löhndorf, A., Irsch, J., Spangfort, M., Miltenyi, S., Hunzelmann, N., Assenmacher, M., Radbruch, A., & Schmitz, J. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199904)29:04<1406::aid-immu1406>3.0.co;2-p · Cited by 135
Bekker, V., Scherpbier, H. J., Pajkrt, D., Jurriaans, S., Zaaijer, H. L., & Kuijpers, T. W. (2006) · PEDIATRICS · doi:10.1542/peds.2005-2616 · Cited by 103 · cited 3×
“Antiretroviral therapy permits only partial restoration of the memory B cell compartment (4).”
BackgroundNanan, R. K. H., Heinrich, D., Frosch, M., & Kreth, H. W. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00328-0 · Cited by 95
Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children
Obaro, S., Pugatch, D. L., & Luzuriaga, K. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)01106-5 · Cited by 94 · cited 2×
“To obtain an optimal response upon vaccination, a preserved humoral and cellular response is required (12).”
BackgroundCagigi, A., Mowafi, F., Dang, L. V. P., Tenner‐Racz, K., Atlas, A., Grützmeier, S., Rácz, P., Chiodi, F., & Nilsson, A. (2008) · Blood · doi:10.1182/blood-2008-02-140426 · Cited by 90 · cited 1×
“This may lead to defective B/T cell contacts during germinal center reactions thus impairing the maintenance of specific antibodies during secondary immune responses (35).”
BackgroundSelf-citationD'Orsogna, L. J. A., Krueger, R. G., McKinnon, E., & French, M. A. (2007) · AIDS · doi:10.1097/qad.0b013e32828642c7 · Cited by 86 · cited 1×
“Several authors suggested that phenotypic and functional alterations in the B cell compartment persist in HIV-1-infected patients despite HAART treatment (3, 4, 7, 8).”
BackgroundJaspan, H. B., Lawn, S. D., Safrit, J. T., & Bekker, L.-G. (2006) · AIDS · doi:10.1097/01.aids.0000210602.40267.60 · Cited by 81
Borkowsky, W., Rigaud, M., Krasinski, K., Moore, T., Lawrence, R. M., & Pollack, H. J. (1992) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)80899-6 · Cited by 75 · cited 1×
“Indeed, impaired humoral responses to vaccinations have been reported in HIV-1-infected children despite successful HAART (9, 10).”
BackgroundDIETZ, V. J., Gałazka, A., LOON, F. P. L. V., & Cochi, S. L. (1997) · Europe PMC (PubMed Central) · Cited by 70
Primary HIV-1 Infection Sets the Stage for Important B Lymphocyte Dysfunctions
Titanji, K., Chiodi, F., Bellocco, R., Schepis, D., Cagigi, A., Osorio, L. M., Tassandin, C., Tambussi, G., Grützmeier, S., Lopalco, L., et al. (2005) · Retrovirology · doi:10.1186/1742-4690-2-s1-p95 · Cited by 61 · cited 4×
“The apparent paradox of HIV-1-infected individuals remaining seronegative with standard serologic diagnostic procedures is a peculiarity of HIV-1 infection when HAART is started during PHI (31, 32).”
BackgroundSelf-citationB cell immunopathology during HIV-1 infection: Lessons to learn for HIV-1 vaccine design
Cagigi, A., Nilsson, A., Milito, A. D., & Chiodi, F. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.11.063 · Cited by 61
Self-citationZanchetta, M., Anselmi, A., Vendrame, D., Rampon, O., Giaquinto, C., Mazza, A., Accapezzato, D., Barnaba, V., & Rossi, A. D. (2008) · Antiviral Therapy · doi:10.1177/135965350801300105 · Cited by 53 · cited 2×
“This is a common phenomenon among HIV-1-infected infants receiving HAART early in life (21, 30).”
BackgroundJiang, W., Lederman, M. M., Mohner, R. J., Rodriguez, B. A., Nedrich, T. M., Harding, C. V., & Sieg, S. F. (2008) · Journal of Virology · doi:10.1128/jvi.00660-08 · Cited by 40
Abzug, M. J., Song, L., Fenton, T., et al. (2007) · PEDIATRICS · doi:10.1542/peds.2007-0729 · Cited by 37
Preserved immune system in long-term asymptomatic vertically HIV-1 infected children
Resino, S., Correa‐Rocha, R., Bellón, J. M., & Muñoz‐Fernández, M. Á. (2003) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2003.02116.x · Cited by 37 · cited 1×
“This is in accordance with a previous report showing that a preserved response to in vitro stimulation to tetanus toxoid is associated with long-term non progressive status in HIV-1 vertically-infected children (33).”
ResultRomiti, M. L., Cancrini, C., Gattinara, G. C., Cesare, S. D., Ciaffi, P., Bernardi, S., de Gasperis, M. R., Halapi, E. C., & Rossi, P. (2001) · AIDS · doi:10.1097/00002030-200111090-00002 · Cited by 28
Self-citationPrevention of Mother-to-Child Transmission of HIV Infection
Katherine, L., & John, L. S. (2005) · Clinical Infectious Diseases · doi:10.1086/427294 · Cited by 19
Cited by
Moir, S., Buckner, C. M., Ho, J., Wang, W., Chen, J., Waldner, A. J., Posada, J. G., Kardava, L., O'Shea, M. A., Kottilil, S., et al. (2010) · Blood · doi:10.1182/blood-2010-05-285528 · Cited by 282
Kerneis, S., Launay, O., Turbelin, C., Batteux, F., Hanslik, T., & Boelle, P.-Y. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit937 · Cited by 190
B‐cell responses to HIV infection
Moir, S., & Fauci, A. S. (2017) · Immunological Reviews · doi:10.1111/imr.12502 · Cited by 163
Metadata
- Authors
- Pensieroso, S., Cagigi, A., Palma, P., Nilsson, A., Capponi, C., Freda, E., Bernardi, S., Thorstensson, R., Chiodi, F., & Rossi, P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-05-12
- Volume
- 106
- Issue
- 19
- Pages
- 7939-7944
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2154931971
- Cited by
- 165
- References
- 39
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.